92 completed, 12 unknown, 11 terminated, 5 recruiting. 32 Phase 4, 29 Phase 3, 22 Phase 2, 10 Not applicable, 10 Phase 1.
Follow Secondary Hyperparathyroidism: new trials by email Literature Review of Secondary Hyperparathyroidism trials Research Report on Secondary Hyperparathyroidism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis PLS240, Standard of Care - Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism | Phase 3 | Not yet recruiting | Pathalys Pharma | 56 | 2026-10-30 | 2026-10-22 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants CTAP101 - CKD Stage 3, CKD Stage 4 | Phase 2 | Recruiting | OPKO Health, Inc. | 40 | 2026-08-05 | 2026-08-20 |
| A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism [14C] SHR6508 Injection - Secondary Hyperparathyroidism | Phase 1 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 5 | 2024-12-23 | 2026-03-23 |
| Intraoperative Parathyroid Hormone Monitoring to Guide Surgery in Renal hyperparathyroIdism Intraoperative parathyroid hormone (IOPTH) monitoring - Secondary Hyperparathyroidism, Tertiary Hyperparathyroidism | Not applicable | Unknown | McMaster University | 60 | 2024-10-01 | 2024-08-07 |
| The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD Dialysate calcium 1.50 mmol/L - Secondary Hyperparathyroidism, End-stage Kidney Disease | Phase 2 | Unknown | Iain Bressendorff | 48 | 2024-08-01 | 2024-05-03 |
| The Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 498 | 2024-06-14 | 2025-12-12 |
| Quality of Life Change in Patients Undergoing Parathyroidectomy With End-stage Renal Failure Quality of life progression after parathyroidectomy - Secondary Hyperparathyroidism, End Stage Renal Failure | Unknown | Chunling Jiang | 80 | 2024-04-15 | 2024-04-23 | |
| Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism Single-cell sequencing - Secondary Hyperparathyroidism | Active not recruiting | China-Japan Friendship Hospital | 12 | 2023-11-10 | 2024-12-27 | |
| A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj. Chronic Kidney Disease 5D, Secondary Hyperparathyroidism | Recruiting | Boryung Pharmaceutical Co., Ltd | 1000 | 2023-10-19 | 2024-12-12 | |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Completed | Pathalys Pharma | 412 | 2023-05-15 | 2025-09-09 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD) | Phase 3 | Completed | Pathalys Pharma | 362 | 2023-04-28 | 2025-09-09 |
| A Study of SHR6508 in Secondary Hyperparathyroidism SHR6508, Cinacalcet - Secondary Hyperparathyroidism | Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 75 | 2023-02-24 | 2023-06-18 |
| Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT Parathyroid Gland Disease, Secondary Hyperparathyroidism | Completed | Fifth Affiliated Hospital, Sun Yat-Sen University | 15 | 2023-02-06 | 2023-09-13 | |
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism CTAP101, Placebo - Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | Phase 3 | Terminated | OPKO Health, Inc. | 2 | 2023-01-31 | 2025-07-25 |
| Precision Medicine Approaches to Renal Osteodystrophy miRNAseq analysis, Standard treatment for bone disorder - Renal Osteodystrophy, Chronic Kidney Diseases | Recruiting | Thomas Nickolas | 40 | 2022-12-21 | 2026-06-12 | |
| A Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508；Placebo - Secondary Hyperparathyroidism | Phase 1 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 54 | 2022-03-10 | 2023-08-08 |
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism Paricalcitol, Placebo - Secondary Hyperparathyroidism | Phase 3 | Unknown | Chengdu Suncadia Medicine Co., Ltd. | 84 | 2022-02-01 | 2022-02-10 |
| Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Teriparatide - Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 3 | Completed | Saint Petersburg State University, Russia | 20 | 2021-03-01 | 2022-11-10 |
| Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary Hyperparathyroidism total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2) - Secondary Hyperparathyroidism, Myocardial Dysfunction | Completed | Mersin University | 37 | 2021-01-01 | 2024-01-03 | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis Etelcalcetide - Secondary Hyperparathyroidism | Phase 3 | Recruiting | Amgen | 24 | 2019-12-20 | 2026-08-21 |
Showing 20 of 124. Sign in to see all of them.
Hyperparathyroidism, Secondary (124) · Renal Insufficiency, Chronic (46) · Kidney Failure, Chronic (22) · Chronic Kidney Disease-Mineral and Bone Disorder (11) · Hyperparathyroidism (11) · Renal Insufficiency (8) · Kidney Diseases (7) · Vitamin D Deficiency (7) · Hypercalcemia (6) · Parathyroid Diseases (5) · Vascular Calcification (3) · Calcinosis (2) · Fractures, Bone (2) · Hyperphosphatemia (2) · Hypertrophy, Left Ventricular (2)
Endocrine System Diseases (124) · Parathyroid Diseases (119) · Hyperparathyroidism (113) · Pathological Conditions, Signs and Symptoms (69) · Female Urogenital Diseases (67) · Female Urogenital Diseases and Pregnancy Complications (67) · Male Urogenital Diseases (67) · Pathologic Processes (67) · Urogenital Diseases (67) · Urologic Diseases (67) · Disease Attributes (66) · Chronic Disease (65) · Kidney Diseases (60) · Renal Insufficiency (52) · Nutritional and Metabolic Diseases (27)
Cinacalcet (29) · paricalcitol (26) · 1 alpha-hydroxyergocalciferol (10) · Calcitriol (9) · etelcalcetide hydrochloride (8) · Standard of Care (4) · Vitamin D (3) · alfacalcidol (3) · maxacalcitol (3) · Ergocalciferols (2) · Sevelamer (2) · Teriparatide (2) · ASP7991 (1) · Calcium (1) · Calcium Carbonate (1)
Amgen (19) · AbbVie (prior sponsor, Abbott) (11) · Abbott (11) · Kyowa Kirin Co., Ltd. (6) · Genzyme, a Sanofi Company (4) · OPKO Health, Inc. (4) · Shanghai Hengrui Pharmaceutical Co., Ltd. (4) · KAI Pharmaceuticals (3) · OPKO IP Holdings II, Inc. (3) · Pathalys Pharma (3) · Sanwa Kagaku Kenkyusho Co., Ltd. (3) · Papageorgiou General Hospital (2) · Saint Petersburg State University, Russia (2) · The University of Hong Kong (2) · Astellas Pharma Inc (1)
United States (40) · Japan (14) · China (12) · Spain (9) · Germany (7) · Greece (7) · Italy (7) · Poland (7) · Russia (7) · Portugal (6) · Austria (5) · Czechia (5) · South Korea (5) · Turkey (Türkiye) (5) · Belgium (4)
Joel Melnick, MD (4) · Ann Eldred, MD (2) · Christos Argyropoulos, MD (2) · Efstathios Mitsopoulos, MD (2) · M D (2) · Akhtar Ashfaq, MD (1) · Anat Tsur, MD (1) · Andrey Strugovshchikov, MD (1) · Angela YM Wang, MD PhD (1) · Angela YM Wang, MD, PhD (1) · Astrid Dworan-Timler (1) · Astrid Seeberger, PhD, A/Prof (1)
PMID 11114639, PMID 11229970, PMID 11576947, PMID 14668730, PMID 15689407, PMID 15698460, PMID 15711996, PMID 15726399, PMID 15828905, PMID 15983958, PMID 16105056, PMID 17556697, PMID 18793528, PMID 19018785, PMID 19778452, PMID 19836494, PMID 20435429, PMID 22202993, PMID 22387567, PMID 23186957, PMID 23222688, PMID 23705925, PMID 24128439, PMID 24214232, PMID 24500308, PMID 24970869, PMID 25112372, PMID 25404192, PMID 25710802, PMID 25851955, PMID 25887067, PMID 25950238, PMID 26059012, PMID 26200645, PMID 26429790, PMID 26800781, PMID 27080930, PMID 28332096, PMID 29525393, PMID 30955188, PMID 31651370, PMID 33825489, PMID 34774334, PMID 35176038, PMID 35529086, PMID 35559350, PMID 35872799, PMID 36512619, PMID 36869794, PMID 37696667
2008 (2), 2009 (2), 2023 (2), 2017 (1), R01DK110871 (1), R01DK134101 (1)